

***Fiscal Year 2014 Amyotrophic Lateral Sclerosis Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-14-ALSRP-TDA</p>	<p>Independent investigators at all academic levels.</p>	<ul style="list-style-type: none"> • Supports preclinical development of therapeutics for amyotrophic lateral sclerosis (ALS). • Specific focus areas include: <ul style="list-style-type: none"> ○ Development of high-throughput screens and model systems. ○ Development of pharmacological agents up to Investigational New Drug submission. ○ Pilot current Good Manufacturing Practices production or formulation/stability studies. • Preliminary data relevant to the phase of preclinical development are required. • Clinical trials are <u>not</u> allowed under this mechanism. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$1,500,000 in direct costs. • More cost-effective studies not requesting the full funding amount are encouraged. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application: May 13, 2014 5:00 p.m. Eastern time (ET)</p> <p>Application: August 20, 2014 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-14-ALSRP-TIA</p>	<p>Investigators at all academic levels</p>	<ul style="list-style-type: none"> • Supports early-stage research relative to novel therapeutic development for ALS. • Studies should be hypothesis-based, but have a clearly defined impact on and relevance to therapeutic development for ALS. • Innovation and impact are primary criteria. • Preliminary data are <u>not</u> required. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$400,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application: May 13, 2014 5:00 p.m. ET</p> <p>Application: August 20, 2014 11:59 p.m. ET</p>